LifeMD Declares $0.5546875 Cash Dividend for Preferred Stockholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10h ago
0mins
Source: Globenewswire
- Dividend Declaration: LifeMD's Board of Directors has authorized a cash dividend of $0.5546875 per share for holders of its 8.875% Series A Cumulative Preferred Stock, scheduled for payment on January 15, 2026, reflecting the company's commitment to shareholder returns.
- Record Date: The record date for this dividend is set for January 5, 2026, ensuring that shareholders on this date will receive the dividend, which enhances investor confidence in the company's financial stability.
- Business Context: LifeMD is a leading provider of virtual primary care services and pharmacy solutions, addressing over 200 conditions, and leverages its vertically integrated digital care platform to improve access to high-quality healthcare.
- Future Outlook: While the current dividend announcement indicates a stable financial position, future performance and dividend payments will still be influenced by market conditions and the company's operational performance.
LFMD
$3.5+Infinity%1D
Analyst Views on LFMD
Wall Street analysts forecast LFMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFMD is 9.67 USD with a low forecast of 6.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.000
Low
6.00
Averages
9.67
High
15.00
Current: 4.000
Low
6.00
Averages
9.67
High
15.00
About LFMD
LifeMD, Inc. is a provider of virtual healthcare services and pharmacy services. The Company offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The Company owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
